HLTH: How AMGEN is Transforming Patient Engagement and Trial Diversity
Technology can be used to address critical healthcare gaps and improve clinical trial diversity.
In this episode, Dr. Marisa Cruz, Vice President of Global Digital Medicine at AMGEN, shares her insights into AMGEN’s forward-thinking digital health initiatives. From the company’s ambitious goal to reduce cardiovascular incidents to innovations in AI-driven clinical trial diversity, Dr. Cruz discusses how cutting-edge technologies are being integrated to enhance patient outcomes and make healthcare more accessible. She also highlights the company’s initiatives to empower patients directly, allowing them to take a proactive role in their health through digital engagement. Dr. Cruz dives into the future of digital health and patient-centered care, spotlighting how innovation can bridge gaps in accessibility and improve health outcomes globally. This episode was sponsored by Amgen.
Tune in and learn how AI and machine learning are bridging the gaps in healthcare!
About Marisa Cruz:
Dr. Marisa Cruz is the Vice President of Global Digital Medicine at AMGEN, a renowned global biotechnology company. An endocrinologist and internist, she continues to practice medicine at UCSF, bringing a clinical perspective to her work in digital health. Dr. Cruz oversees AMGEN’s digital health strategy, focusing on harnessing data and technology to improve patient outcomes and bridge healthcare accessibility gaps.
Things You’ll Learn:
AMGEN is driving innovation in digital health with initiatives like the LATTICE Consortium, aiming to reduce cardiovascular incidents by 50%.
AI and machine learning are playing a crucial role in improving clinical trial diversity and accessibility.
Emerging digital health trends, including implementation science and patient-centered care, are reshaping the future of healthcare.
AMGEN’s patient engagement platform, PARC, empowers patients to actively participate in their own healthcare journey.
Resources:
